

SUPPLEMENTARY TABLE S4 Single- and multi-variate logistic regression assessing the risks of having at least one episode of severe acute exacerbation at two years and at three years of follow-up

Method of staging (cutoff values)	Crude OR for ≥ 1 SAE at 2 years (95% CI)	Adjusted OR [#] for ≥ 1 SAE at 2 years (95% CI)	Crude OR for ≥ 1 SAE at 3 years (95% CI)	Adjusted OR [#] for ≥ 1 SAE at 3 years (95% CI)
FEV₁%pred (GOLD)				
1 (≥80%)	1	1	1	1
2 (≥50% and <80)	1.02 (0.38-2.76)	0.92 (0.32-2.67)	0.79 (0.30-2.09)	0.66 (0.24-1.82)
3 (≥30% and <50)	2.32 (0.87-6.18)	1.84 (0.63-5.37)	1.90 (0.72-5.03)	1.37 (0.50-3.78)
4 (<30%)	0.74 (0.16-3.35)	0.57 (0.11-2.96)	1.17 (0.30-4.60)	0.81 (0.19-3.47)
FEV₁%pred(quartiles)				
1 (≥69.3%)	1	1	1	1
2 (≥53.6% and <69.3)	1.12 (0.47-2.67)	0.93 (0.37-2.32)	0.93 (0.39-2.20)	0.78 (0.32-1.89)
3 (≥41.0% and <53.6)	2.70 (1.22-5.96)*	2.17 (0.94-4.99)	2.27 (1.02-5.03)*	1.84 (0.81-4.19)
4 (<41.0%)	1.77 (0.78-4.00)	1.42 (0.58-3.51)	1.93 (0.88-4.23)	1.41 (0.60-3.29)
Z score				
1 (≥-1.70)	1	1	1	1
2 (≥-2.57 and < -1.70)	0.89 (0.38-2.12)	0.73 (0.30-1.81)	0.78 (0.33-1.82)	0.63 (0.26-1.50)
3 (≥-3.17 and < -2.57)	3.09 (1.43-6.71)**	2.58 (1.13-5.89)*	2.13 (0.97-4.69)	1.67 (0.73-3.80)
4 (<-3.17)	1.28 (0.56-2.90)	1.24 (0.49-3.15)	1.78 (0.81-3.88)	1.51 (0.63-3.60)
(FEV₁·Ht⁻²)_A				
1 (≥0.63)	1	1	1	1
2 (≥0.47 and <0.63)	1.30 (0.57-2.96)	1.00 (0.41-2.44)	1.55 (0.67-3.56)	1.35 (0.56-3.26)
3 (≥0.36 and <0.47)	2.02 (0.91-4.49)	1.40 (0.58-3.37)	2.06 (0.91-4.66)	1.56 (0.65-3.74)
4 (<0.36)	1.96 (0.85-4.52)	1.38 (0.54-3.43)	2.27 (0.98-5.24)	1.63 (0.66-4.05)
(FEV₁·Ht⁻²)_B				
1 (≥0.50)	1	1	1	1
2 (≥0.40 and < 0.30)	1.44 (0.69-2.97)	1.15 (0.53-2.48)	1.40 (0.67-2.90)	1.13 (0.52-2.43)
3 (≥0.30 and < 0.40)	2.37 (1.19-4.69)*	1.87 (0.89-3.94)	2.17 (1.10-4.30)*	1.72 (0.83-3.58)
4 (< 0.30)	1.34 (0.51-3.52)	1.04 (0.36-3.02)	1.52 (0.58-3.98)	1.09 (0.38-3.14)
FEV₁·Ht⁻³				
1 (≥0.38)	1	1	1	1
2 (≥0.29 and <0.38)	1.21 (0.54-2.70)	0.99 (0.42-2.34)	1.51 (0.67-3.42)	1.33 (0.57-3.10)
3 (≥0.22 and <0.29)	1.83 (0.86-3.93)	1.35 (0.59-3.10)	1.76 (0.80-3.83)	1.36 (0.59-3.12)
4 (<0.22)	1.58 (0.70-3.58)	1.10 (0.44-2.73)	2.04 (0.90-4.60)	1.44 (0.60-3.47)

FEV₁Q

1 (≥ 3.38)	1	1	1	1
2 (≥ 2.50 and < 3.38)	1.63 (0.70-3.80)	1.35 (0.54-3.40)	1.75 (0.74-4.14)	1.59 (0.64-3.95)
3 (≥ 1.90 and < 2.50)	2.07 (0.91-4.74)	1.46 (0.59-3.64)	2.25 (0.97-5.21)	1.81 (0.73-4.45)
4 (< 1.90)	2.37 (1.04-5.41)*	1.72 (0.68-4.37)	2.65 (1.15-6.12)*	2.03 (0.82-5.04)

69 patients had at least 1 episode of SAE at 2 years of follow-up, and 75 patients had at least 1 episode of SAE at 3 years of follow-up. FEV₁, forced expiratory volume in 1 second; FEV₁%pred, percentage of predicted FEV₁; FEV₁·Ht², FEV₁ over height squared; FEV₁·Ht³, FEV₁ over height cubed; FEV₁Q, FEV₁ quotient; GOLD, the Global Initiative for Chronic Obstructive Lung Disease; OR, odds ratio; SAE, severe acute exacerbation; 95% CI, 95% confidence interval.

: Adjustment was made for age, body mass index, Charlson comorbidity index, smoking status, and history of SAE in the preceding year. * : $P < 0.05$; ** : $P < 0.005$.